Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

Author(s): Lorenzo Falchi1;Santosha A. Vardhana1;Gilles A. Salles1
Source: Blood (2023) 141 (5): 467–480
Original Article
Professional photo of Maem Hussein, MD

Dr. Maen Hussein's Thoughts

This is not a trial, but really a very nice review article, too. A good read especially as we may start prescribing those meds locally.
Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last 2 decades following the introduction of highly active immunotherapies such as rituximab. Since then, the field has continued to witness tremendous progress with the introduction of newer, more potent immunotherapeutics, including chimeric antigen receptor T-cell therapy, which have received regulatory approval for and currently play a significant role in the treatment of these diseases. Bispecific antibodies (BsAb) are a novel class of off-the-shelf T-cell redirecting drugs and are among the most promising immunotherapeutics for lymphoma today. BsAb may target various cell-surface antigens and exist in different formats. Anti-CD20xCD3 BsAb have demonstrated remarkable single-agent activity in patients with heavily pretreated B-NHL with a manageable toxicity profile dominated by T-cell overactivation syndromes. Much work remains to be done to define the optimal setting in which to deploy these drugs for B-NHL treatment, their ideal combination partners, strategies to minimize toxicity, and, perhaps most importantly, pharmacodynamic biomarkers of response and resistance. In this review, we provide an update on BsAb development in B-NHL, from discovery to clinical applications, highlighting the achievements, limitations, and future directions of the field.
 

Author Affiliations

1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

This is a really encouraging look at chemo-free frontline therapy for symptomatic or high-burden FL and MZL. Eight cycles of mosunetuzumab alone produced a 71% complete response (CR) rate, escalation to pola-obinutuzumab for PET-positive patients pushed CR to 86%, and 2-year progression-free survival (PFS) was 89% with no maintenance. Toxicity was impressively outpatient-friendly: CRS was all grade 1, no one needed tocilizumab, and there was no immune effector cell–associated neurotoxicity syndrome (ICANS), though the shingles and HSV reactivations make a good case for antiviral prophylaxis. It's a small single-center study with two CD20-negative relapses to keep in mind, but the ctDNA–PET concordance hints at an MRD-guided "treat less when you can" future.

Read More »

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

Progression-free survival was improved in the tafa-len-R-CHOP group vs the R-CHOP with 2-year progression-free survival rates of 71·1vs 62·9% toxicity was higher with tafa-len-R-CHOP with a higher rate of fatal treatment-emergent adverse events, but more overall deaths the RCHOP arm. It is early to add Len taf because of toxicity esp with OS survival and deep response data being immature.

Read More »

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????

Read More »
Load More